- Home
- PSHG vs EVAX Comparison
PSHG vs EVAX Comparison
Compare PSHG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- EVAX
- Stock Information
- Founded
- PSHG 2010
- EVAX 2008
- Country
- PSHG Greece
- EVAX Denmark
- Employees
- PSHG N/A
- EVAX N/A
- Industry
- PSHG Marine Transportation
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSHG Consumer Discretionary
- EVAX Health Care
- Exchange
- PSHG Nasdaq
- EVAX Nasdaq
- Market Cap
- PSHG 20.1M
- EVAX 16.3M
- IPO Year
- PSHG N/A
- EVAX 2021
- Fundamental
- Price
- PSHG $1.37
- EVAX $1.52
- Analyst Decision
- PSHG Strong Buy
- EVAX Strong Buy
- Analyst Count
- PSHG 1
- EVAX 2
- Target Price
- PSHG $6.50
- EVAX $10.00
- AVG Volume (30 Days)
- PSHG 45.6K
- EVAX 76.2K
- Earning Date
- PSHG 05-29-2025
- EVAX 05-27-2025
- Dividend Yield
- PSHG N/A
- EVAX N/A
- EPS Growth
- PSHG N/A
- EVAX N/A
- EPS
- PSHG 1.12
- EVAX N/A
- Revenue
- PSHG $87,445,000.00
- EVAX $3,344,000.00
- Revenue This Year
- PSHG N/A
- EVAX $102.45
- Revenue Next Year
- PSHG $31.45
- EVAX $100.30
- P/E Ratio
- PSHG $1.22
- EVAX N/A
- Revenue Growth
- PSHG N/A
- EVAX 4480.82
- 52 Week Low
- PSHG $1.31
- EVAX $1.20
- 52 Week High
- PSHG $2.58
- EVAX $21.80
- Technical
- Relative Strength Index (RSI)
- PSHG 37.20
- EVAX 43.85
- Support Level
- PSHG $1.34
- EVAX $1.20
- Resistance Level
- PSHG $1.55
- EVAX $1.46
- Average True Range (ATR)
- PSHG 0.08
- EVAX 0.13
- MACD
- PSHG -0.00
- EVAX 0.04
- Stochastic Oscillator
- PSHG 20.83
- EVAX 64.03
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.